Endocrine therapy for advanced/metastatic breast cancer.

[1]  L. Chow,et al.  Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Piccart,et al.  Abstract P6-04-02: Final progression-free survival analysis of BOLERO-2: a phase III trial of everolimus for postmenopausal women with advanced breast cancer , 2012 .

[3]  A. Leo,et al.  Final analysis of overall survival for the Phase III CONFIRM trial: fulvestrant 500 mg versus 250 mg , 2012 .

[4]  M. Gnant,et al.  Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer. , 2012, European journal of cancer.

[5]  I. Ray-Coquard,et al.  Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Robert B Livingston,et al.  Combination anastrozole and fulvestrant in metastatic breast cancer. , 2012, The New England journal of medicine.

[7]  J. Bergh,et al.  FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Forbes,et al.  The sequential use of endocrine treatment for advanced breast cancer: where are we? , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  C. Hudis,et al.  1st International consensus guidelines for advanced breast cancer (ABC 1). , 2012, Breast.

[10]  M. Ellis,et al.  A phase I study of BKM120, a novel oral selective phosphatidylinositol-3-kinase (PI3K) inhibitor, in combination with fulvestrant in postmenopausal women with estrogen receptor positive metastatic breast cancer. , 2012 .

[11]  S. Johnston,et al.  Randomized phase II open-label study of abiraterone acetate (AA) plus low-dose prednisone (P) with or without exemestane (E) in postmenopausal women with ER+ metastatic breast cancer (MBC) progressing after letrozole or anastrozole therapy. , 2012 .

[12]  E. Winer,et al.  SU2C phase Ib study of pan-PI3K inhibitor BKM120 with letrozole in ER+/HER2- metastatic breast cancer (MBC). , 2012 .

[13]  A. Howell,et al.  2LBA Fulvestrant Alone or with Concomitant Anastrozole Vs Exemestane Following Progression On Non-steroidal Aromatase Inhibitor – First Results of the SoFEa Trial (CRUKE/03/021 & CRUK/09/007) (ISRCTN44195747) , 2012 .

[14]  M. Beckmann,et al.  Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial. , 2012, Breast.

[15]  J. Thigpen.  Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer , 2012 .

[16]  J. Balko,et al.  Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Dowsett,et al.  Phase I study of abiraterone acetate (AA) in patients (pts) with estrogen receptor- (ER) or androgen receptor (AR) -positive advanced breast carcinoma resistant to standard endocrine therapies. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  R. Schiff,et al.  Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II Study , 2011, Clinical Cancer Research.

[19]  M. Dowsett,et al.  Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women. , 2010, European journal of cancer.

[20]  M. Lichinitser,et al.  Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  V. Valero,et al.  Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  P. Neven,et al.  Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2) , 2010, Breast Cancer Research and Treatment.

[23]  V. Valero,et al.  Phase II, Randomized Trial to Compare Anastrozole Combined with Gefitinib or Placebo in Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer , 2010, Clinical Cancer Research.

[24]  A. Muggia.  Endocrine Therapy for Advanced Breast Cancer: Beyond Tamoxifen and Aromatase Inhibitors , 2010 .

[25]  M. Campone,et al.  Anastrozole and goserelin combination as first treatment for premenopausal receptor positive advanced or metastatic breast cancer: A phase II trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Mackey,et al.  Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Saeed Sadeghi,et al.  Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. Ellis,et al.  Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  M. Ellis,et al.  Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. , 2009, JAMA.

[30]  Cynthia X. Ma,et al.  Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT , 2009 .

[31]  J. Fricker.  San Antonio Breast Cancer Symposium. , 2009, The Lancet. Oncology.

[32]  M. Piccart,et al.  Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  P. Lønning,et al.  Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? , 2008, The oncologist.

[34]  M. Piccart,et al.  Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  A. Buzdar,et al.  Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  J. Robertson.  Fulvestrant (Faslodex) -- how to make a good drug better. , 2007, The oncologist.

[37]  R. Elledge.  Second- and Third-generation Aromatase Inhibitors as First-line Endocrine Therapy in Postmenopausal Metastatic Breast Cancer Patients: A Pooled Analysis of the Randomised Trials , 2007 .

[38]  O. Garrone,et al.  Sequential Treatment with Exemestane and Non-Steroidal Aromatase Inhibitors in Advanced Breast Cancer , 2006, Oncology.

[39]  M. Mottolese,et al.  New aromatase inhibitors as second‐line endocrine therapy in postmenopausal patients with metastatic breast carcinoma , 2005, Cancer.

[40]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[41]  J. Robertson.  Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective. , 2004, Cancer treatment reviews.

[42]  Manuel Hidalgo,et al.  Inhibition of mTOR Activity Restores Tamoxifen Response in Breast Cancer Cells with Aberrant Akt Activity , 2004, Clinical Cancer Research.

[43]  J. Baselga,et al.  Phase II, 3-arm study of CCI-779 in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer: preliminary results. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  Anthony Howell,et al.  Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  H. Lane,et al.  The mTOR pathway in estrogen response: A potential for combining the rapamycin derivative RAD001 with the aromatase inhibitor Letrozole (Femara®) in breast carcinoma , 2004 .

[46]  J. Robertson,et al.  Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer , 2004, British Journal of Cancer.

[47]  P. Lønning,et al.  Phase III Randomized Trial of Droloxifene and Tamoxifen As First-Line Endocrine Treatment of ER/PgR-Positive Advanced Breast Cancer , 2002, Breast Cancer Research and Treatment.

[48]  D. Hayes,et al.  Meta‐analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer , 1999, Breast Cancer Research and Treatment.

[49]  K. Pritchard,et al.  A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: A report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA.1 , 1997, Breast Cancer Research and Treatment.

[50]  J. Forbes,et al.  An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer , 1997, Breast Cancer Research and Treatment.

[51]  J. Robertson,et al.  Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. , 2003, European journal of cancer.

[52]  J. Robertson,et al.  Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. , 2003, European journal of cancer.

[53]  M. Ellis,et al.  Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women , 2003, Cancer.

[54]  Mitch Dowsett,et al.  Aromatase inhibitors in breast cancer. , 2003, The New England journal of medicine.

[55]  C. Osborne,et al.  Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials. , 2003, European journal of cancer.

[56]  C. Boni,et al.  Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  K. Pritchard.  Endocrine therapy of advanced disease: analysis and implications of the existing data. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[58]  A. Howell,et al.  Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  C K Osborne,et al.  Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  P. Lønning.  Aromatase Inhibitors and Inactivators for Breast Cancer Therapy , 2002, Drugs & aging.

[61]  S. Johnston.  Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[62]  S. Glück.  Anastrozole Is Superior to Tamoxifen as First-Line Therapy in Hormone Receptor Positive Advanced Breast Carcinoma Results of Two Randomized Trials Designed for Combined Analysis , 2001 .

[63]  M. Morgan,et al.  Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  J. Robertson,et al.  Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  A. Buzdar,et al.  Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  S. Eppenberger-Castori,et al.  Potential prognostic value of mitogen‐activated protein kinase activity for disease‐free survival of primary breast cancer patients , 2000, International journal of cancer.

[67]  P. Lønning,et al.  Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  L. Dirix,et al.  Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  I. Tannock,et al.  Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  Anthony Howell,et al.  Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma , 1998, Cancer.

[71]  R. Sylvester,et al.  A new standard treatment for advanced premenopausal breast cancer: A meta-analysis of the Combined Hormonal Agent Trialists Group (CHAT) , 1998 .

[72]  D. Campos,et al.  Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[73]  S. Martino,et al.  Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  P. Dombernowsky,et al.  Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  M. Piccart,et al.  Combined treatment with the LHRH-agonist buserelin (LHRH-A) and tamoxifen (TAM) vs single treatment with each drug alone in premenopausal metastatic breast cancer. Final results of EORTC study 10881 , 1998 .

[76]  A Howell,et al.  Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  P. Kenemans,et al.  LHRH agonist treatment of breast cancer and gynecological malignancies: a review. , 1996, European journal of obstetrics, gynecology, and reproductive biology.

[78]  A. Howell,et al.  A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. , 1996, European journal of cancer.

[79]  J. Klijn,et al.  PP-8-1 Combined estroyen suppression and receptor (ER) blockade by buserelin (LHRH-A) and tamoxifen (TAM) in premenopausal metastatic breast cancer: Preliminary results of a 3-arm randomized study (EORTC 10881) , 1996 .

[80]  S. Hilsenbeck,et al.  Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. , 1995, Journal of the National Cancer Institute.

[81]  V. Jordan,et al.  Tamoxifen: toxicities and drug resistance during the treatment and prevention of breast cancer. , 1995, Annual review of pharmacology and toxicology.

[82]  A. Howell,et al.  A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer. , 1995, European journal of cancer.

[83]  P. Sismondi,et al.  Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[84]  V. Gebski,et al.  Randomized comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on treatment response and survival in patients with metastatic breast cancer. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[85]  S. Lundgren.  Progestins in breast cancer treatment. A review. , 1992, Acta oncologica.

[86]  G. Evans,et al.  Weight changes in women with metastatic breast cancer treated with megestrol acetate: a comparison of standard versus high-dose therapy. , 1990, Seminars in oncology.

[87]  S. Dahrouge,et al.  Comparison of antiestrogen and progestogen therapy for initial treatment and consequences of their combination for second-line treatment of recurrent breast cancer. , 1990, Seminars in oncology.

[88]  I. Jackson,et al.  Antioestrogens in the management of hormone-dependent cancer. , 1988, Cancer treatment reviews.

[89]  S. Sedlacek.  An overview of megestrol acetate for the treatment of advanced breast cancer. , 1988, Seminars in oncology.

[90]  A. Howell,et al.  A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[91]  J. Ingle,et al.  Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[92]  Morgan Lr.  Megestrol acetate v tamoxifen in advanced breast cancer in postmenopausal patients. , 1985 .

[93]  Allegra Jc,et al.  Mechanisms of action of progestational agents. , 1985 .

[94]  S. Kiefer,et al.  Mechanisms of action of progestational agents. , 1985, Seminars in oncology.

[95]  J. Ingle,et al.  Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer. , 1982, American journal of clinical oncology.

[96]  J. Ingle,et al.  Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. , 1981, The New England journal of medicine.

[97]  K. Pritchard,et al.  Tamoxifen therapy in premenopausal patients with metastatic breast cancer. , 1980, Cancer treatment reports.

[98]  McGuire Wl,et al.  Hormone receptors: their role in predicting prognosis and response to endocrine therapy. , 1978, Seminars in oncology.

[99]  E. Jensen,et al.  The use of estrogen antagonists in hormone receptor studies. , 1972, Gynecologic investigation.

[100]  I. Todd,et al.  A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474 , 1971, British Journal of Cancer.

[101]  J. Cates,et al.  Treatment of advanced breast cancer by trans-sphenoidal hypophysectomy. , 1968, British Journal of Cancer.

[102]  H. Randall,et al.  The results of adrenalectomy in advanced breast cancer in 500 consecutive patients. , 1967, Surgery, gynecology & obstetrics.

[103]  B. Kennedy,et al.  Surgery as an adjunct to hormone therapy of breast cancer , 1957, Cancer.

[104]  C. Huggins,et al.  Inhibition of human mammary and prostatic cancers by adrenalectomy. , 1952, Cancer research.

[105]  G. Beatson.  On the Treatment of Inoperable Cases of Carcinoma of the Mamma: Suggestions for a New Method of Treatment, with Illustrative Cases , 1896, Transactions. Medico-Chirurgical Society of Edinburgh.